据悉，公司已建立由11款候选药物组成的管线，包括2个低风险产品TY-9591（核心产品）、TY-302（关键产品），5款创新临床产品，4款处于临床前阶段的产品。值得注意的是，公司已获得国家药监局对其核心产品TY-9591的II期和III期临床试验的IND批准，同时正在进行产品TY-302和TY-2136b的关键临床试验。Tongyuan Kang Medicine-B (02410) rose nearly 20% in the afternoon, reaching a high of 38.5 Hong Kong dollars, hitting a new high since its listing, more than doubling from the IPO price of 12.1 Hong Kong dollars. As of the time of publication, it has risen by 11.52%, to 34.85 Hong Kong dollars, with a turnover of 11.8925 million Hong Kong dollars.
According to the Securities Times app, Tongyuan Kang Medicine-B (02410) rose nearly 20% in the afternoon, reaching a high of 38.5 Hong Kong dollars, hitting a new high since its listing, more than doubling from the IPO price of 12.1 Hong Kong dollars. As of the time of publication, it has risen by 11.52%, to 34.85 Hong Kong dollars, with a turnover of 11.8925 million Hong Kong dollars.
The prospectus shows that Tongyuan Kang Medicine is a clinical-stage biopharmaceutical company, with a core business model that includes the discovery, development, and commercialization of small molecule drugs and other innovative drug types (such as PROTAC) internally to address unmet needs in the cancer field, especially in the area of lung cancer.
It is reported that the company has established a pipeline consisting of 11 candidate drugs, including 2 low-risk products TY-9591 (core product), TY-302 (key product), 5 innovative clinical products, and 4 preclinical products. It is worth noting that the company has obtained approval from the National Medical Products Administration for Phase II and III clinical trials of its core product TY-9591, and is currently conducting key clinical trials for products TY-302 and TY-2136b.
